Behavioral Neuroscience, Psychopharmacology, Attention, Executive functions, Cognitive Aging, Alzheimer’s disease, Drug addiction
Vinay Parikh, Ph.D. is an Associate Professor of Psychology and head of the Neurochemistry and Cognition Laboratory at Temple University. He is also the Director of Neuroscience Program in the College of Liberal Arts. Dr. Parikh’s research generally concerns neuromodulation of cognitive processes specifically those involved in attention and executive functions. A particular focus of his work is to delineate neurochemical signaling mechanisms that regulate functional interactions between the prefrontal cortex and other cortical and subcortical regions, and how alterations in discrete neurochemical circuits impact top-down cognitive control of behavior during the aging process and following chronic use of psychoactive drugs. Additionally, Dr. Parikh and his group are interested in exploring how the interplay of genes and environment influence the cognitive reserve capacity. Cognitive impairments constitute the core features of age-related neurodegenerative disorders such as Alzheimer’s disease and psychopathological states associated with drug addiction, schizophrenia and other mental disorders. The long term goal of his research is to identify potential biomarkers to develop psychotherapeutic approaches for the treatment of these cognitive and mental conditions. Dr. Parikh’s research involves the use of rodent models to examine cognitive alterations in the normative and pathological brain. A broad range of neuroscientific methods and approaches are used in his research including the sophisticated operant behavioral paradigms, in vivo electrochemical recordings, vector-based genetic manipulations and protein biochemistry. Dr. Parikh has directed many research projects and his current research is funded by the National Institute of Health.
Dr. Parikh received his Ph.D. in Life Sciences/Pharmacology from Punjabi University (India). After leading the Pharmacology group in Drug Discovery division at Sun Pharmaceutical Industries Ltd., he joined the Medical College of Georgia (Augusta, GA) as a postdoctoral fellow to obtain training in Neurochemistry/Neuropsychopharmacology. He integrated perspectives of systems and behavioral/cognitive neuroscience into his research by acquiring further postdoctoral training in Psychobiology and Neuroscience from the Ohio State University (Columbus, OH) and the University of Michigan (Ann Arbor, MI). Dr. Parikh is a faculty member of the Psychology Department at Temple University since 2009. He has published over 50 peer-reviewed articles and contributed many book chapters. He has also received several honors and awards including the Research Faculty Recognition Award from the University of Michigan (2008); New Investigator Award in Alzheimer’s disease from the American Federation for Aging Research (2010), and Young Investigator Awards from NARSAD (2010) and the American College of Neuropsychopharmacology (2014).
Parikh V, Naughton SX, Yegla B, Guzman DM. Impact of partial dopamine depletion on cognitive flexibility in BDNF heterozygous mice. Psychopharmacology 2016; 233: 1361-1375.
Parikh V, Kutlu M, Gould TJ. nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: current trends and perspectives. Schizophrenia Research 2016; 171: 1-15.
Parikh V, Cole RD, Patel PJ, Poole RL, Gould TJ. Cognitive control deficits during mecamylamine-precipitated withdrawal in mice: Possible links to frontostriatal BDNF imbalance. Neurobiology of Learning and Memory 2016; 128: 110-116.
Cole RD, Poole RL, Guzman D, Gould TJ, Parikh V. Contributions of β2 subunit-containing nAChRs to chronic nicotine-induced alterations in cognitive flexibility in mice. Psychopharmacology 2015; 232: 1207-1217.
Yegla B, Parikh V. Rejuvenating procholinergic treatments for cognition enhancement in AD: current challenges and future prospects. Frontiers in Systems Neuroscience 2015; 8: 254.
Parikh V, Bernard CS, Naughton SX, Yegla B. Interactions between Aβ oligomers and presynaptic cholinergic signaling: age-dependent effects on attentional capacities. Behavioral Brain Research 2014; 274: 30-42.
Parikh V, Naughton SX, Shi X, Kelley LK, Yegla B, Rawls SM, Unterwald EM. Cocaine- induced neuroadaptations in striatal glutamate signaling and behavioral sensitization. Neurochemistry International 2014; 75:54-65.
Yegla B, Parikh V. Effects of sustained proNGF blockade on attentional capacities in aged rats with compromised cholinergic system. Neuroscience 2014; 261:118-132.
D’Amore DE, Tracy BA, Parikh V. Exogenous BDNF facilitates strategy shifting by modulating glutamate dynamics in the dorsal striatum. Neuropharmacology 2013; 75: 312-323.
Ortega LA, Tracy BA, Gould TJ, Parikh V. Effect of chronic low- and high-dose nicotine on cognitive flexibility in C57BL/6J mice. Behavioral Brain Research 2013; 238: 134-145.
Parikh V, St. Peters M, Blakely RD, Sarter M. The presynaptic choline transporter imposes limits on sustained cortical acetylcholine release and attention. The Journal of Neuroscience 2013; 33: 2326-2337.
Parikh V, Howe WM, Welchko R, Naughton SX, Han D, D’Amore DE, Turner DL, Sarter M. Diminished trkA receptor signaling reveals cholinergic-attentional vulnerability of aging. European Journal of Neuroscience 2013; 37: 278-293.
Parikh V, Ji J, Decker MW, Sarter M. Prefrontal β2 subunit-containing and α7 nAChRs differentially control glutamatergic and cholinergic signaling. The Journal of Neuroscience 2010; 30: 3518-3530.
Parikh V, Kozak R, Martinez V, Sarter M. Prefrontal acetylcholine release controls cue detection on multiple time scales. Neuron 2007; 56: 141-54.
Sarter M, Parikh V. Choline transporters, cholinergic transmission and cognition. Nature Reviews Neuroscience 2005; 6:48-56.
Cellular Neuroscience (NSI 2122)
Neurobiology of Learning and Memory (PSY 3566)
Neurobiology of Executive Function and Dysfunction (PSY 8310)
Psychopharmacology (PSY 3561)
Techniques in Neuroscience (NSI 3087)
Writing-intensive Capstone in Neuroscience (NSI 4197)